Skip to main content
SpringerLink
Log in

Should We Encourage Over-The-Counter Statins?

A Population Perspective for Coronary Heart Disease Prevention

  • Original Research Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Background

Prescribed statin therapy has contributed to a dramatic reduction in primary and secondary coronary heart disease (CHD). In the UK, simvastatin is currently available without prescription; however, the US FDA rejected an application for nonprescription lovastatin in 2005.

Objective and methods

We used population impact measures for three hypothetical levels of CHD risk to estimate the number of CHD events that would be prevented in the US over 5 years under three scenarios: (i) prescription-only regulations; (ii) approval of over-the-counter (OTC) statins; and (iii) implementation of lifestyle interventions.

Results

For people at very low risk of CHD, 429 299 CHD events could be prevented by the availability of OTC statins and 560 243 CHD events could be prevented among this group by implementing lifestyle interventions. For those at moderate risk of CHD, 244 388 CHD events could be prevented by OTC statins compared with 318 866 by lifestyle interventions. For people at high risk of CHD, prescription statins could prevent 374 897 CHD events over the next 5 years.

Conclusions

Provision of OTC statins to US adults at low or moderate risk of CHD would have a greater impact on CHD prevention than providing prescription statins for those at high risk of CHD. Provision of OTC statins alongside lifestyle interventions among those at low or moderate risk of CHD could substantially reduce the number of CHD events in the population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326(7404): 1423–7.

    Article  PubMed  CAS  Google Scholar 

  2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279(20): 1615–22.

    Article  PubMed  CAS  Google Scholar 

  3. Shepherd J. Who should receive a statin these days? Lessons from recent clinical trials. J Intern Med 2006; 260(4): 305–19.

    Article  PubMed  CAS  Google Scholar 

  4. Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4086M1.htm [Accessed 2006 Oct 20].

  5. Dyer O. Consumers’ Association voices concern at over the counter statins. BMJ 2004; 329(7461): 310–e.

    Article  PubMed  Google Scholar 

  6. Heller RF, Dobson AJ. Disease impact number and population impact number: population perspectives to measures of risk and benefit. BMJ 2000; 321(7266): 950–2.

    Article  PubMed  CAS  Google Scholar 

  7. Heller RF, Edwards R, Mcelduff P. Implementing guidelines in primary care: can population impact measures help? BMC Public Health 2003; 3: 7.

    Article  PubMed  Google Scholar 

  8. Heller RF, Page J. A population perspective to evidence based medicine: ‘evidence for population health’. J Epidemiol Community Health 2002; 56(1): 45–7.

    Article  PubMed  CAS  Google Scholar 

  9. Ford ES, Giles WH, Mokdad AH. The distribution of 10-year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 2004; 43(10): 1791–6.

    Article  PubMed  Google Scholar 

  10. National Institutes of Health. Third report of the National cholesterol Education Program Expert Pannel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Washington, DC: National Institutes of Health, 2001. Report no: 01–3670.

    Google Scholar 

  11. Wilsom PW, D’Agostimo RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–47.

    Article  Google Scholar 

  12. Ketola E, Sipila R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med 2000; 32(4): 239–51.

    Article  PubMed  CAS  Google Scholar 

  13. Gotto AM. Over-the-counter statins are worth considering in primary prevention of cardiovascular disease. Circulation 2006; 114(12): 1310–4.

    Article  PubMed  Google Scholar 

  14. LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006; 40(7–8): 1274–9.

    Article  Google Scholar 

  15. Eriksson KM, Westborg CJ, Eliasson MCE. A randomized trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors: the Bjorknas study. Scand J Public Health 2006; 34(5): 453–61.

    Article  PubMed  Google Scholar 

  16. Brass EP. Consumer behavior in the setting of over-the-counter statin availability: lessons from the consumer use study of OTC Mevacor. Am J Cardiol 2004; 94(9): 22F–9F.

    Article  PubMed  Google Scholar 

  17. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279(18): 1458–62.

    Article  PubMed  CAS  Google Scholar 

  18. Population projections: United States by state, age and sex, for the years 2004–2030 [online]. Available from URL: URL: http://wonder.cdc.gov/WONDER/help/PopulationProjections.HTML [Accessed 2006 Nov 21].

  19. Gotto AM. Over-the-counter statins and cardiovascular disease prevention: perspectives, challenges, and opportunities. Clin Pharmacol Ther 2005; 78(3): 213–7.

    Article  PubMed  Google Scholar 

  20. Sever P, Dahlöf B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149–58.

    Article  PubMed  CAS  Google Scholar 

  21. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004; 68: 860–7.

    Article  Google Scholar 

  22. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28(1): 26–35.

    Article  PubMed  CAS  Google Scholar 

  23. Barter PJ, Rye KA. The argument against the appropriateness of over-the-counter statins. Circulation 2006; 114(12): 1315–20.

    Article  PubMed  Google Scholar 

  24. Hughes S. Over the counter statins. J Cardivasc Nurs 2004; 19(6): 430–1.

    Google Scholar 

  25. Abrams J. Over-the-counter statins: a new controversy. Nat Clin Pract Cardiovasc Med 2005; 2(4): 174–5.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. National Primary Care Research and Development Centre, University of Manchester, Williamson Building, Oxford Road, Manchester, M13 9PL, England, UK

    Islay Gemmell

  2. Clinical Epidemiology and Public Health Unit, University of Manchester, Manchester, England

    Arpana Verma & Roger A. Harrison

  3. Bolton Primary Care Trust, Bolton, England

    Roger A. Harrison

Authors
  1. Islay Gemmell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arpana Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roger A. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Islay Gemmell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gemmell, I., Verma, A. & Harrison, R.A. Should We Encourage Over-The-Counter Statins?. Am J Cardiovasc Drugs 7, 299–302 (2007). https://doi.org/10.2165/00129784-200707040-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200707040-00007

Keywords

Search

Navigation